Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
80M
-
Number of holders
-
75
-
Total 13F shares, excl. options
-
21.8M
-
Shares change
-
-304K
-
Total reported value, excl. options
-
$544M
-
Value change
-
-$5.68M
-
Number of buys
-
49
-
Number of sells
-
-25
-
Price
-
$24.92
Significant Holders of Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) as of Q2 2020
86 filings reported holding AKRO - Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2020.
Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) has 75 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.8M shares
of 80M outstanding shares and own 27.28% of the company stock.
Largest 10 shareholders include Apple Tree Partners IV, L.P. (5.42M shares), venBio Partners LLC (3.15M shares), JANUS HENDERSON GROUP PLC (2.74M shares), Versant Venture Management, LLC (2.12M shares), HILLHOUSE CAPITAL ADVISORS, LTD. (1.06M shares), BlackRock Inc. (1.03M shares), ALKEON CAPITAL MANAGEMENT LLC (998K shares), Cormorant Asset Management, LP (593K shares), Vivo Capital, LLC (591K shares), and VANGUARD GROUP INC (540K shares).
This table shows the top 75 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.